ADENOSINE injection

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

ADENOSINE (UNII: K72T3FS567) (ADENOSINE - UNII:K72T3FS567)

Commercializzato da:

WOCKHARDT USA LLC.

INN (Nome Internazionale):

ADENOSINE

Composizione:

ADENOSINE 3 mg in 1 mL

Via di somministrazione:

INTRAVENOUS

Tipo di ricetta:

PRESCRIPTION DRUG

Indicazioni terapeutiche:

Intravenous adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration.  It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ).1 Adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm.  In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. - Second- or third-degree A-V block (except in patients with a functioning artificial pacemaker). - Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functio

Stato dell'autorizzazione:

Abbreviated New Drug Application

Scheda tecnica

ADENOSINE - ADENOSINE INJECTION
WOCKHARDT USA LLC.
----------
ADENOSINE INJECTION, USP
FOR RAPID BOLUS INTRAVENOUS USE
DESCRIPTION
Adenosine is an endogenous nucleoside occurring in all cells of the
body. It is chemically 6-amino-9-
β-D-ribofuranosyl-9-H-purine and has the following structural
formula:
Adenosine is a white, odorless crystalline powder. It is soluble in
water and practically insoluble in
alcohol. Solubility increases by warming and lowering the pH.
Adenosine is not chemically related to
other antiarrhythmic drugs. Adenosine injection, USP is a sterile,
nonpyrogenic solution for rapid
bolus intravenous injection. Each mL contains 3 mg adenosine and 9 mg
sodium chloride in Water for
Injection. The pH of the solution is between 4.5 and 7.5.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Adenosine injection slows conduction time through the A-V node, can
interrupt the reentry pathways
through the A-V node, and can restore normal sinus rhythm in patients
with paroxysmal supraventricular
tachycardia (PSVT), including PSVT associated with
Wolff-Parkinson-White Syndrome.
Adenosine injection is antagonized competitively by methylxanthines
such as caffeine and theophylline,
and potentiated by blockers of nucleoside transport such as
dipyridamole. Adenosine injection is not
blocked by atropine.
HEMODYNAMICS
The intravenous bolus dose of 6 or 12 mg adenosine injection usually
has no systemic hemodynamic
effects. When larger doses are given by infusion, adenosine decreases
blood pressure by decreasing
peripheral resistance.
PHARMACOKINETICS
Intravenously administered adenosine is rapidly cleared from the
circulation via cellular uptake,
primarily by erythrocytes and vascular endothelial cells. This process
involves a specific
transmembrane nucleoside carrier system that is reversible,
nonconcentrative, and bidirectionally
symmetrical. Intracellular adenosine is rapidly metabolized either via
phosphorylation to adenosine
monophosphate by adenosine kinase, or via deamination to inosine by
adenosine deaminase in the